Hemophilia B Pipeline Assessment, 2023 | In-depth Insights Into the Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Emerging Therapies, and Treatment Algorithm | Key Companies - CSL Behring/uniQure (Hemgenix/Etranacog

Currently, the major treatment options for Hemophilia B are Recombinant Factor IX Concentrates, Plasma-Derived Factor IX Concentrates, and Fresh Frozen Plasma. Fresh frozen plasma is extracted from human blood and is used only when factor IX concentrate is not available to treat patients with factor IX deficiency. Presently, gene therapies are also gaining immense popularity due to their potential to cure this disease and the anticipated one-time infusion.

Globally, several major pharma and biotech giants such as ApcinteX, Novo Nordisk, Sanofi, Pfizer, Sangamo Therapeutics, Catalyst Biosciences, uniQure, Alnylam, CSL Behring, Freeline Therapeutics, and others, are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Hemophilia B. If launched, these emerging potential candidates could pose an adverse threat to current Hemophilia B pharmaceutical giants by means of their potential to transform the standard of care for Hemophilia B patients.

"Hemophilia B Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hemophilia B Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Hemophilia B Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Hemophilia B Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hemophilia B market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More About the Emerging Therapies and Evolving Treatment Algorithms:
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Hemophilia B Pipeline Emerging Drugs - Mechanism of Action (MOA)
- Antithrombin III inhibitor
- Lipoprotein-associated
- Coagulation inhibitor inhibitors
- Gene transference
- Factor IX replacement
- Serine protease inhibitors

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hemophilia B Therapeutics Analysis
The fundamental treatment of hemophilia B is to replace factor IX to achieve adequate blood clotting and to prevent complications associated with the disorder. Currently, the replacement of factor IX to achieve a sufficient level is commonly done utilizing recombinant products or with products derived from human blood or plasma. Recombinant factor IX therapy is the recommended treatment for individuals with hemophilia B.

The Leading Companies in the Hemophilia B Therapeutics Market Include:
- UniQure Biopharma B.V
- CSL Behring
- Spark Therapeutics
- Genzyme, a Sanofi Company
- Alnylam Pharmaceuticals
- Novo Nordisk
- Pfizer
- UniQure Biopharma B.V.
- ApcinteX Ltd
- Freeline Therapeutics
- Sangamo Therapeutics
And Many Others

Hemophilia B Drugs Covered and Analyzed in the Report Include:
- AMA005: Amarna therapeutics
- CB 2679d-GT: Catalyst Biosciences
- SerpinPC: Centessa Pharmaceuticals
- Concizumab: Novo Nordisk
- BBM-H901: Belief BioMed
- FLT180a: Freeline Therapeutics
- Etranacogene dezaparvovec (AMT-061): CSL Behring/uniQure
- SB-FIX: Sangamo Therapeutics
- Fitusiran: Sanofi/Alnylam Pharmaceuticals)
- Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Hemophilia B Current Treatment Patterns
4. Hemophilia B - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hemophilia B Late-Stage Products (Phase-III)
7. Hemophilia B Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hemophilia B Discontinued Products
13. Hemophilia B Product Profiles
14. Hemophilia B Key Companies
15. Hemophilia B Key Products
16. Dormant and Discontinued Products
17. Hemophilia B Unmet Needs
18. Hemophilia B Future Perspectives
19. Hemophilia B Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:

Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Address: 428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.